Patents by Inventor Michael Lahn

Michael Lahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PI3K-? inhibitor for use in treatment regimens
    Patent number: 12605389
    Abstract: A compound or a pharmaceutically acceptable salt thereof for use in a method of treatment of a disease or condition in which signalling through the PI3K? pathway is pathologically implicated in patients, for example cancer and inflammatory or autoimmune diseases. The compound is provided at a specified dose and has been found to have a favourable safety profile in humans, in particular with regard to hepatotoxicity, diarrhoea/colitis, respiratory infections, and hematologic toxicities.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: April 21, 2026
    Assignee: iOnctura SA
    Inventors: Catherine Pickering, Lars Van Der Veen, Michael Lahn, Rebeca Zorrilla, Zoë Johnson
  • AUTOTAXIN (ATX) INHIBITOR FOR THE TREATMENT OF PANCREATIC CANCER
    Publication number: 20250057820
    Abstract: An autotaxin (ATX) inhibitor or a pharmaceutically acceptable salt thereof for use in a method of treatment of pancreatic cancer in a patient, optionally wherein the method further comprises administration of a TGF-? pathway inhibitor and/or an additional chemotherapeutic agent.
    Type: Application
    Filed: June 8, 2022
    Publication date: February 20, 2025
    Inventors: Zoë JOHNSON, Marcel DEKEN, Michael LAHN, Davide MELISI
  • A PI3K-DELTA INHIBITOR FOR USE IN TREATMENT REGIMENS
    Publication number: 20240058351
    Abstract: A compound or a pharmaceutically acceptable salt thereof for use in a method of treatment of a disease or condition in which signalling through the PI3K? pathway is pathologically implicated in patients, for example cancer and inflammatory or autoimmune diseases. The compound is provided at a specified dose and has been found to have a favourable safety profile in humans, in particular with regard to hepatotoxicity, diarrhoea/colitis, respiratory infections, and hematologic toxicities.
    Type: Application
    Filed: March 29, 2022
    Publication date: February 22, 2024
    Inventors: Catherine PICKERING, Lars VAN DER VEEN, Michael LAHN, Rebeca ZORRILLA, Zoë JOHNSON
  • Modulation of gamma delta T cells to regulate airway hyperresponsiveness
    Publication number: 20050008627
    Abstract: Disclosed is a method for regulation of airway hyperresponsiveness by modulating the action of ?? T cells in a patient. Also disclosed are methods for identifying compounds that regulate airway hyperresponsiveness by modulating ?? T cell action.
    Type: Application
    Filed: March 24, 2004
    Publication date: January 13, 2005
    Inventors: Erwin Gelfand, Willi Born, Michael Lahn, Arihiko Kanehiro